Leukemia regression by vascular disruption and antiangiogenic therapy.
about
Functional and Biological Role of Endothelial Precursor Cells in Tumour Progression: A New Potential Therapeutic Target in Haematological MalignanciesIn vivo spectral and fluorescence microscopy comparison of microvascular function after treatment with OXi4503, Sunitinib and their combination in Caki-2 tumors.Molecular targets for selective killing of TRAIL-resistant leukemic cells.Functional integration of acute myeloid leukemia into the vascular niche.Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503.Activation of the vascular niche supports leukemic progression and resistance to chemotherapyLeukemia Mediated Endothelial Cell Activation Modulates Leukemia Cell Susceptibility to Chemotherapy through a Positive Feedback Loop MechanismA perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessmentOverexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia.Gene expression profiles in BCL11B-siRNA treated malignant T cells.Angiogenesis in acute myeloid leukemia and opportunities for novel therapies.Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions.Cardiovascular toxicity profiles of vascular-disrupting agents.Oncolytic virotherapy for hematological malignancies.Serial monitoring of human systemic and xenograft models of leukemia using a novel vascular disrupting agent.Preclinical Activity of the Vascular Disrupting Agent OXi4503 against Head and Neck CancerIdentification of leukemia stem cells in acute myeloid leukemia and their clinical relevance.Targeting the vascular endothelial growth factor in hematologic malignancies.Tubulin-interactive stilbene derivatives as anticancer agents.Synthesis and anti-cancer screening of novel heterocyclic-(2H)-1,2,3-triazoles as potential anti-cancer agents.Angiogenesis and proliferation index in patients with acute leukemia: a prospective studyIn vitro and in vivo effects of an anti-mouse endoglin (CD105)-immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours.A VEGFR-3 antagonist increases IFN-γ expression on low functioning NK cells in acute myeloid leukemia.Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer.Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway.Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.Acute Myeloid Leukemia and the Bone Marrow Niche-Take a Closer Look
P2860
Q26770838-1D6AB0E6-74E8-4953-AB30-EB4A78673974Q33738607-0635C09B-6116-4342-8156-B6A12D767E3AQ33891400-7A5D0F11-AD21-4DB2-BDCF-BFB8A8D763C9Q34207361-649368E0-D534-4DBA-BB80-B758EC60DF15Q34491366-7C69D13A-8F48-495C-AE59-4094CDD431ACQ34622824-1F2C49BB-27C3-440B-B1A2-39FCB65F9BC8Q34656484-2945E5EB-8F77-4539-8ECC-5D8562DA4942Q34765364-E2C9F302-79BC-48DE-A6DE-B5A1F6B725ACQ34849602-A9A97861-F74A-429E-9AF2-93469CBF0F9DQ35041552-BA1AF0C8-ADA9-4946-AAA7-FC1948B1D1FEQ35196950-B44E2177-187C-410D-8B18-F90CD0C48471Q35533586-5A9AF118-36F3-4EAB-968B-C5DE5C7A37DDQ35584746-9472A382-5C9C-4D8D-A367-8DC3F1B18442Q35692095-1BFAB053-1402-4A1D-A14B-F39CA4AF8522Q36225973-4767F8B1-E576-4900-B096-2C6E4BB09C3EQ36506995-D0C53AC9-4D9B-4C74-B460-8363F6D60B73Q38010349-C42A05C7-9C81-4886-92D5-D2F9F6DDBD08Q38038645-F4B275DD-9AD6-4501-9573-FA7453B9DA05Q38118663-5FD91DC5-0C2A-4F47-B8DA-6B59CE2788FFQ38779271-3F741237-AF1B-4FE4-A81E-BE501D9AFD06Q38784730-43927608-E91F-488B-951B-5F07767C8B27Q39257411-06816645-51E9-4CD5-A011-1FEE9E470B27Q45077403-6458CC2F-1C62-4F29-826C-508C1B6A1359Q51795514-8B273149-CD29-4EAD-B0D4-0422C279318CQ51843632-4AF2C84A-51D8-4B8F-AC78-4B543BA7B7BEQ55354182-FE3E610F-7382-46F5-A81B-F8FB117034B2Q58122645-090547A3-7585-4803-95AC-CF3AEADFAB08
P2860
Leukemia regression by vascular disruption and antiangiogenic therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Leukemia regression by vascular disruption and antiangiogenic therapy.
@ast
Leukemia regression by vascular disruption and antiangiogenic therapy.
@en
Leukemia regression by vascular disruption and antiangiogenic therapy.
@nl
type
label
Leukemia regression by vascular disruption and antiangiogenic therapy.
@ast
Leukemia regression by vascular disruption and antiangiogenic therapy.
@en
Leukemia regression by vascular disruption and antiangiogenic therapy.
@nl
prefLabel
Leukemia regression by vascular disruption and antiangiogenic therapy.
@ast
Leukemia regression by vascular disruption and antiangiogenic therapy.
@en
Leukemia regression by vascular disruption and antiangiogenic therapy.
@nl
P2093
P2860
P1433
P1476
Leukemia regression by vascular disruption and antiangiogenic therapy.
@en
P2093
Amy M Meacham
Christopher R Cogle
Dietmar W Siemann
Edward W Scott
Gerard J Madlambayan
Koji Hosaka
Marda Jorgensen
P2860
P304
P356
10.1182/BLOOD-2009-06-230474
P407
P577
2010-05-14T00:00:00Z